Table 4 Lung microbiology at baseline and at month 12.
| Azithromycin | Placebo | |||
|---|---|---|---|---|
| Baseline | Month 12 | Baseline | Month 12 | |
| No of samples analysed | 34 | 31 | 36 | 35 |
| No of samples with positive cultures | 29 | 24 | 29 | 29 |
| No of positive cultures of common CF pathogens | ||||
| Staphylococcus aureus | 19 | 15 | 20 | 20 |
| Methicillin resistant S aureus | 2 | 2 | 5 | 5 |
| Haemophilus influenzae | 6 | 4 | 11 | 9 |
| Pseudomonas aeruginosa | 5 | 3 | 4 | 5 |
| Stenotrophomonas maltophilia | 0 | 1 | 0 | 2 |
| Achromobacter xylosoxidans | 1 | 1 | 1 | 0 |
| Burkholderia cepacia | 1 | 1 | 0 | 0 |
| Aspergillus fumigatus | 3 | 5 | 4 | 5 |
Lung microbiology was documented from respiratory tract samples cultured for the common CF pathogens at baseline and at month 12.